nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
ASCOT – old or new drugs for blood pressure?
|
Ritter, James |
|
2006 |
61 |
3 |
p. 363 |
artikel |
2 |
Clinically relevant drug interactions with antiepileptic drugs
|
Perucca, Emilio |
|
2006 |
61 |
3 |
p. 246-255 |
artikel |
3 |
Curriculum development in pharmacotherapy: testing the ability of preclinical medical students to learn therapeutic problem solving in a randomized controlled trial
|
Vollebregt, J. A. |
|
2006 |
61 |
3 |
p. 345-351 |
artikel |
4 |
Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status
|
Uno, Tsukasa |
|
2006 |
61 |
3 |
p. 309-314 |
artikel |
5 |
Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids
|
Morrish, Glynn A. |
|
2006 |
61 |
3 |
p. 326-335 |
artikel |
6 |
Disposition and pharmacodynamics of propofol during isovolaemic haemorrhage followed by crystalloid resuscitation in humans
|
Takizawa, Eri |
|
2006 |
61 |
3 |
p. 256-261 |
artikel |
7 |
Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes
|
Miura, Masatomo |
|
2006 |
61 |
3 |
p. 315-320 |
artikel |
8 |
Genetic polymorphisms in KCNQ1, HERG, KCNE1 and KCNE2 genes in the Chinese, Malay and Indian populations of Singapore
|
Koo, Seok Hwee |
|
2006 |
61 |
3 |
p. 301-308 |
artikel |
9 |
Hydroxylation of lansoprazole in poor metabolizers of CYP2C19
|
Furuta, Takahisa |
|
2006 |
61 |
3 |
p. 361 |
artikel |
10 |
Initial phase of chronic medication use; patients’ reasons for discontinuation
|
Hugtenburg, J. G. |
|
2006 |
61 |
3 |
p. 352-354 |
artikel |
11 |
Low incidence of hypertensive disorders of pregnancy in women treated with spiramycin for toxoplasma infection
|
Todros, T. |
|
2006 |
61 |
3 |
p. 336-340 |
artikel |
12 |
Orphan drug development is progressing too slowly
|
Joppi, Roberta |
|
2006 |
61 |
3 |
p. 355-360 |
artikel |
13 |
Pharmacokinetics of a new testosterone transdermal delivery system, TDS®-testosterone in healthy males
|
Chik, Z. |
|
2006 |
61 |
3 |
p. 275-279 |
artikel |
14 |
Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone
|
Simpson, Julie A. |
|
2006 |
61 |
3 |
p. 289-300 |
artikel |
15 |
Rare diseases and orphan drugs
|
Aronson, J. K. |
|
2006 |
61 |
3 |
p. 243-245 |
artikel |
16 |
Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy
|
Resch, Ulrike |
|
2006 |
61 |
3 |
p. 262-274 |
artikel |
17 |
Tadalafil pharmacokinetics in healthy subjects
|
Forgue, S. Thomas |
|
2006 |
61 |
3 |
p. 280-288 |
artikel |
18 |
The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia
|
Davies, Benjamin J. |
|
2006 |
61 |
3 |
p. 321-325 |
artikel |
19 |
When gatekeepers meet the sentinel: the impact of a prior authorization requirement for cefuroxime on the prescribing behaviour of community-based physicians
|
Kahan, Natan R. |
|
2006 |
61 |
3 |
p. 341-344 |
artikel |